NPS+ (US) [CLL]

LONDON, Nov. 28, 2017 /PRNewswire/ -- There are various options available to US oncologists and haematologists to treat chronic lymphocytic leukaemia (CLL). Clearly some of these options are achieving greater levels of loyalty and satisfaction than others – but why? What are the key...